Macrogenics (MGNX) Income from Continuing Operations (2012 - 2026)
Macrogenics (MGNX) reported Income from Continuing Operations of 38328000.0 for Q1 2026, up 10.27% year-over-year from 34758195.41 in Q1 2025, and down 171.31% quarter-over-quarter from 14127000.0 in Q4 2025.
Macrogenics (MGNX) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Income from Continuing Operations data on file, last reported at 38328000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 38328000.0, up 10.27% year-over-year; the trailing twelve-month figure through Mar 2026 was 71884000.0 (down 25.04% YoY), and the FY2025 annual result was 74592000.0, down 11.39% from the prior year.
- Income from Continuing Operations eased to 38328000.0 in Q1 2026 per MGNX's latest filing, from 14127000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 56309000.0 in Q3 2024 and troughed at 66638000.0 in Q1 2022.
- A 5-year average of 27961764.71 and a median of 38328000.0 in 2026 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 511.87% in 2023, then surged 258.61% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 11983000.0 in 2022, then sank by 511.87% to 49354000.0 in 2023, then surged by 68.75% to 15421000.0 in 2024, then gained by 8.39% to 14127000.0 in 2025, then slumped by 171.31% to 38328000.0 in 2026.
- Business Quant data shows MGNX's Income from Continuing Operations at 38328000.0 in Q1 2026, 14127000.0 in Q4 2025, and 16822000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | -38.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.33 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | -36.25 Mn |
| Mar 31, 2025 | -42.72 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | 56.31 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -54.88 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -45.74 Mn |
| Mar 31, 2023 | -39.08 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -66.64 Mn |
| Dec 31, 2021 | -58.24 Mn |
| Sep 30, 2021 | -52.99 Mn |
| Jun 30, 2021 | -40.28 Mn |